Share on StockTwits

Petmed Express (NASDAQ:PETS) CFO Bruce S. Rosenbloom sold 1,500 shares of the stock on the open market in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $13.50, for a total value of $20,250.00. Following the transaction, the chief financial officer now directly owns 41,184 shares of the company’s stock, valued at approximately $555,984. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Petmed Express (NASDAQ:PETS) traded down 0.97% on Friday, hitting $13.29. 55,757 shares of the company’s stock traded hands. Petmed Express has a one year low of $12.13 and a one year high of $17.75. The stock has a 50-day moving average of $13.22 and a 200-day moving average of $13.96. The company has a market cap of $265.3 million and a P/E ratio of 14.91.

Petmed Express (NASDAQ:PETS) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.23 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.22 by $0.01. The company had revenue of $48.60 million for the quarter, compared to the consensus estimate of $55.02 million. During the same quarter in the prior year, the company posted $0.23 earnings per share. The company’s quarterly revenue was down 4.9% on a year-over-year basis. On average, analysts predict that Petmed Express will post $0.92 earnings per share for the current fiscal year.

PETS has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Petmed Express in a research note on Friday, May 23rd. They now have a $14.00 price target on the stock. Analysts at Northcoast Research downgraded shares of Petmed Express from a “buy” rating to a “neutral” rating in a research note on Thursday, May 1st.

PetMed Express, Inc (NASDAQ:PETS) and its subsidiaries, doing business as 1-800-PetMeds, is a pet pharmacy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.